Silver Grove Financial Group’s Takeda Pharmaceutical TAK Stock Holding History

Silver Grove Financial Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.2K	Buy	+883	New	+$14.6K	0.01%	753

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Silver Grove Financial Group's TAK Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Takeda Pharmaceutical (TAK) in Q2 2026: 883 shares worth $14.2K. The stake represents 0.01% of the portfolio and ranks #753 among its holdings.

376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Silver Grove Financial Group held 883 shares of Takeda Pharmaceutical worth $14.2K as of Q2 2026.
Takeda Pharmaceutical was a new Silver Grove Financial Group position in Q2 2026.
Takeda Pharmaceutical made up 0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #753 holding.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.